Saniona (Q2 review): With focus into the clinic - Redeye
Redeye returns with an update following Saniona's Q2 update and recent events in the company. We largely reiterate our fundamental valuation and introduce a mixed fundamental/relative valuation, which screens "attractively priced".
ANNONS
Redeye returns with an update following Saniona's Q2 update and recent events in the company. We largely reiterate our fundamental valuation and introduce a mixed fundamental/relative valuation, which screens "attractively priced".